Ocata Therapeutics Inc fka OCAT

[SteveMQ]

Response from Investor's relations at ACTC...FYI

Steve,

I am responding to the email you sent Dan Schustack. There have been many
questions from investors regarding the timing of the two multicenter Phase I/II
trials that Advanced Cell Technology will be conducting in Dry Age-Related
Macular Degeneration (Dry AMD), the leading cause of blindness in people over
65, and Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular
degeneration. The company believes that the activities in preparation for the
trials will result in both trials commencing in the first half of 2011.
The company is currently in negotiations with four trial sites, and may add one
to two more sites. There is extremely broad interest on the part of leading
ophthalmology clinical centers, and the company is undertaking a very thorough
evaluation of those entities that will be the company’s partners to ensure that
the trials have the highest likelihood of success. Each trial is for 12
patients, set up in 4 cohorts of 3 patients. The company expects to begin both
trials at approximately the same time, and under the protocols agreed with the
FDA, the first patient in each trial will be treated (with the smallest dosage),
and then 6 weeks later patients 2 and 3 in each trial will begin treatment.
Advanced Cell currently expects to stage each set of cohorts about six weeks
apart, with escalating dosages, so patient 4 in each trial would begin around 6
weeks after patients 2 and 3, and so on.
The company currently has sufficient cash on hand plus the availability of
additional cash to more than cover the costs of the trials and the company’s
other operating costs, though Advanced Cell is expecting to be eligible for
grant, low interest loan and other non-dilutive forms of funding to assist in
paying for the trials.
As each of the trials will be open-label, the company may, once the trials
commence, be able to share details on the safety profile and response of the
patients prior to the end of the trials.

Best Regards,

James Young
CEOcast, Inc.
317 Madison Avenue, Suite 1621
New York, NY 10017
212-732-4300